Disposition of 16278 shares by Howard Robin of Nektar Therapeutics at 1.01 subject to Rule 16b-3
| RYCFX Fund | USD 42.49 0.25 0.58% |
Slightly above 62% of Biotechnology Fund's investor base is looking to short. The analysis of overall sentiment of trading Biotechnology Fund Class mutual fund suggests that many investors are alarmed at this time. Biotechnology Fund's investing sentiment can be driven by a variety of factors including economic data, Biotechnology Fund's earnings reports, geopolitical events, and overall market trends.
Biotechnology |
Filed transaction by Nektar Therapeutics Director, Officer: President & Ceo. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at macroaxis.com
Biotechnology Fund Fundamental Analysis
We analyze Biotechnology Fund's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biotechnology Fund using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biotechnology Fund based on its fundamental data. In general, a quantitative approach, as applied to this mutual fund, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Ten Year Return
Ten Year Return Comparative Analysis
Biotechnology Fund is currently under evaluation in ten year return among similar funds. Ten Year Return shows the total annualized return generated from holding a fund for the last 10 years and represents fund's capital appreciation, including dividends losses and capital gains distributions. This return indicator is considered by many investors to be the ultimate measures of fund performance and can reflect the overall performance of the market or market segment it invests in.
Biotechnology Fund Class Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Biotechnology Fund mutual fund to make a market-neutral strategy. Peer analysis of Biotechnology Fund could also be used in its relative valuation, which is a method of valuing Biotechnology Fund by comparing valuation metrics with similar companies.
Peers
Biotechnology Fund Related Equities
| HIIDX | Harbor Diversified | 0.40 | ||||
| MNDWX | Manning Napier | 0.38 | ||||
| DLTZX | Delaware Limited-term | 0.13 | ||||
| GPICX | Guidepath Conservative | 0.10 | ||||
| VYRPX | Voya Solution | 0.1 | ||||
| QDARX | Aqr Diversified | 0.08 | ||||
| SRDAX | Stone Ridge | 0.09 | ||||
| JDJRX | Jhancock Diversified | 0.11 |
Other Information on Investing in Biotechnology Mutual Fund
Biotechnology Fund financial ratios help investors to determine whether Biotechnology Mutual Fund is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Biotechnology with respect to the benefits of owning Biotechnology Fund security.
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |